Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All N‑acetylcysteine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchN-acetylcysteineN-acetylcys.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Safety and Efficacy of N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients

Abdelmonem et al., QJM: An International Journal of Medicine, doi:10.1093/qjmed/hcae070.076
Jun 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
14th treatment shown to reduce risk in February 2021
 
*, now with p = 0.000027 from 24 studies, recognized in 3 countries.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
Retrospective 80 ICU patients reporting no statistically significant differences with NAC treatment, however the actual results are not provided. The study is described as a retrospective observational study however authors also state that "patients were randomized into two equal groups". The "Non NAC" group also received NAC - the study compares high dose treatment over 21 hours versus low dose ongoing treatment.
Abdelmonem et al., 1 Jun 2024, retrospective, peer-reviewed, 4 authors, study period December 2020 - February 2022.
This PaperN-acetylcys..All
{ 'indexed': {'date-parts': [[2024, 7, 4]], 'date-time': '2024-07-04T00:23:57Z', 'timestamp': 1720052637169}, 'reference-count': 0, 'publisher': 'Oxford University Press (OUP)', 'issue': 'Supplement_1', 'license': [ { 'start': { 'date-parts': [[2024, 6, 1]], 'date-time': '2024-06-01T00:00:00Z', 'timestamp': 1717200000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://academic.oup.com/pages/standard-publication-reuse-rights'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2024, 7, 3]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>COVID-19 may cause pneumonia, acute respiratory distress syndrome, ' 'cardiovascular alterations, and multiple organ failure, which have been ascribed to a ' 'cytokinestorm, a systemic inflammatory response, and an attack by the immune system. ' 'Moreover, an oxidative stress imbalance has been demonstrated to occur in COVID- 19 patients. ' 'N- Acetyl-L-cysteine (NAC) is a precursor of reduced glutathione (GSH).</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Aim of the Work</jats:title>\n' ' <jats:p>we retrospectively will investigate safety and efficacy of NAC dose ' 'given in paracetamol toxicity as an adjuvant therapy in critically ill COVID-19 patients with ' 'acute respiratory distress and determine whether NAC in high doses can avoid respiratory ' 'failure in patients with COVID-19.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Patients and Methods</jats:title>\n' ' <jats:p>This was a retrospective observational study in which all cases ' 'were collected from ICU of Ain shams university hospitals during COVID-19 outbreak. All data ' 'were extracted from clinical records. All patients initially admitted to ICU with SPO2 less ' 'than 94 % were included between December 2020 to February 2022. Exclusion Criteria included ' 'Need for immediate mechanical ventilation on admission, known allergy or hypersensitivity to ' 'NAC, end stage renal and liver diseases, heart failure and pregnancy. All patients with ' 'severe COVID-19 (confirmed or suspected received standard care, according to the ' 'institutional protocol.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>Patients were randomized into two equal groups (number (n)=40 each) ' 'as the N1(NAC) group who was given intravenously, initially 150\u2009mg/kg in 200\u2009mL of ' '0.9% NaCL for 60\u2009minutes (first bag), followed by 50\u2009mg/kg in 500\u2009mL of 0.9% ' 'NaCL for 4\u2009hours (second bag), and then 100\u2009mg/kg in 1000\u2009mL of 0.9%NaCL for ' '16\u2009hours (third bag) and N2(Non NAC) group who received intravenously N-acetylcysteine ' '(NAC) 600mg /12hr and The primary endpoint was the need for mechanical ventilation. Secondary ' 'endpoints were time of mechanical ventilation, admission to the intensive care unit (ICU), ' 'time in ICU, and mortality. There were no statistically significant differences between the ' 'two groups (p\u2009&amp;gt;\u20090.05) The effect of NAC on mechanical ventilations, ' 'mortality, ICU stays, and hospital stays is a matter of controverse in ARDS patients. We ' 'found that intravenous high dose of NAC did not improve oxygenation, mortality rate and did ' 'not reduce the requirement for mechanical ventilation when administered for COVID 19 patients ' 'with ARDS. Also, the duration of ICU and hospital stays were relatively prolonged in the ' 'NAC-treated patients. These might be due to prolonged survival time with NAC-treated ' 'patients, but not to be detected with the small single centered trial..</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Conclusion</jats:title>\n' ' <jats:p>Use of high doses of NAC administration can not affect the need of ' 'mechanical ventilation, rate of mortality, the need, duration of ICU admission and hospital ' 'stays for patients with severe COVID-19.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1093/qjmed/hcae070.076', 'type': 'journal-article', 'created': {'date-parts': [[2024, 7, 3]], 'date-time': '2024-07-03T15:11:22Z', 'timestamp': 1720019482000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Safety and Efficacy of N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 ' 'Patients', 'prefix': '10.1093', 'volume': '117', 'author': [ { 'given': 'Hany Saeed', 'family': 'Abdelmonem', 'sequence': 'first', 'affiliation': [ { 'name': 'Intensive Care Department, Faculty of Medicine, Ain Shams ' 'University'}]}, { 'given': 'Hanaa Mohamed Abd', 'family': 'Allah Elgendy', 'sequence': 'additional', 'affiliation': [ { 'name': 'Intensive Care Department, Faculty of Medicine, Ain Shams ' 'University'}]}, { 'given': 'Doaa Mohammed', 'family': 'Kamal El-Din', 'sequence': 'additional', 'affiliation': [ { 'name': 'Intensive Care Department, Faculty of Medicine, Ain Shams ' 'University'}]}, { 'given': 'Eman Mohamed', 'family': 'Elshaer', 'sequence': 'additional', 'affiliation': [ { 'name': 'Intensive Care Department, Faculty of Medicine, Ain Shams ' 'University'}]}], 'member': '286', 'published-online': {'date-parts': [[2024, 7, 3]]}, 'container-title': 'QJM: An International Journal of Medicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://academic.oup.com/qjmed/article-pdf/117/Supplement_1/hcae070.076/58413542/hcae070.076.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/qjmed/article-pdf/117/Supplement_1/hcae070.076/58413542/hcae070.076.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 7, 3]], 'date-time': '2024-07-03T15:11:27Z', 'timestamp': 1720019487000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://academic.oup.com/qjmed/article/doi/10.1093/qjmed/hcae070.076/7705150'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 6, 1]]}, 'references-count': 0, 'journal-issue': { 'issue': 'Supplement_1', 'published-online': {'date-parts': [[2024, 7, 3]]}, 'published-print': {'date-parts': [[2024, 7, 3]]}}, 'URL': 'http://dx.doi.org/10.1093/qjmed/hcae070.076', 'relation': {}, 'ISSN': ['1460-2725', '1460-2393'], 'subject': [], 'published-other': {'date-parts': [[2024, 6, 1]]}, 'published': {'date-parts': [[2024, 6, 1]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit